Uppsala Akademiska Sjukhus

Uppsala 75185

1 studies enrolling now · 6 studies all time

What they study most

ALK+ Advanced NSCLC, ALK-positive Advanced NSCLC, Chronic Idiopathic Constipation, Chronic Lymphocytic Leukemia, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL — Running, not enrolling
• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma — Completed
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer — Completed
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib — Completed
• Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation — Stopped early